Gyre Therapeutics
GYRE
46 hedge funds and large institutions have $51.4M invested in Gyre Therapeutics in 2019 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 12 increasing their positions, 18 reducing their positions, and 6 closing their positions.
67% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 6
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
50% more call options, than puts
Call options by funds: $117K | Put options by funds: $78K
41% more capital invested
Capital invested by funds: $36.5M → $51.4M (+$14.9M)
10% more funds holding
Funds holding: 42 → 46 (+4)
0.11% more ownership
Funds ownership: 8.26% → 8.36% (+0.11%)
33% less repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 18
Top Buyers
| 1 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$1.72M |
| 2 |
Marshall Wace
London,
United Kingdom
|
+$702K |
| 3 |
Two Sigma Investments
New York
|
+$698K |
| 4 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$565K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$443K |
Top Sellers
| 1 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
-$2.27M |
| 2 |
PM
Prosight Management
Dallas,
Texas
|
-$929K |
| 3 |
JP Morgan Chase
New York
|
-$814K |
| 4 |
FM
Fondren Management
Houston,
Texas
|
-$276K |
| 5 |
Morgan Stanley
New York
|
-$226K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SFS
51
Sowell Financial Services
North Little Rock,
Arkansas
| – | -$4K | -120 | Closed |
|
52
Bank of America
Charlotte,
North Carolina
| – | -$503 | -12 | -80% |
|
GYRE Hedge Fund Activity: Q4 2019 in Review
46 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Gyre Therapeutics (GYRE) for Q4 2019, worth a combined $51.4M — up 41% from $36.5M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new GYRE positions and 6 closed out — a net gain of 4 holders — while 12 added to existing stakes and 18 trimmed.
The largest buyer was Stonepine Capital Management, opening a new position worth an estimated $1.72M. The largest seller was Eventide Asset Management, exiting entirely with an estimated $2.27M sold.
- 46 institutional investors held Gyre Therapeutics (GYRE) as of Q4 2019, up from 42 in Q3 2019.
- Funds reported $51.4M of Gyre Therapeutics stock for Q4 2019, up 41% quarter-over-quarter.
- 10 funds opened new Gyre Therapeutics positions in Q4 2019 and 6 closed out, a net change of +4 holders.
- The largest Gyre Therapeutics buyer in Q4 2019 was Stonepine Capital Management, an estimated $1.72M added.
- The largest Gyre Therapeutics seller in Q4 2019 was Eventide Asset Management, an estimated $2.27M sold.
Based on aggregated 13F filings for Q4 2019.